Management

  • David Browning – President

    Mr. Browning is a performance-driven executive with over 22 years of clinical drug development experience working in the contract research organization (CRO) and academic settings. Previously, Mr. Browning helped start and build the international oncology-focused clinical research organization, Medelis, Inc. As Chief Operating Officer and Vice President of Clinical Operations, he made key contributions to the company’s growth by closing more than $50 million in research Continue Reading...

  • Mark Staples, Ph.D. – (CSO) Chief Scientific Officer

    Dr. Mark Staples has helped transform scientifically interesting projects into commercial products intended to serve unmet medical needs for over 25 years. His product development activities include pharmaceutical development of proteins, peptides and small organic molecules. Dr. Staples has extensive experience with project management and compilation of technical (CMC) portion of regulatory submission. Dr. Staples played critical operating and leadership roles in five early Continue Reading...

  • Charles Mazinter – (CEO) Chief Executive Officer

    Mr. Mazinter is an Entrepreneur who has owned and led many businesses. Mr. Mazinter’s skills are diverse and include business start-up & development, marketing, sales, advertising and management. Mr. Mazinter served as the President of Global Pharmacal, Inc., a biopharmaceutical company located at the Texas Research Park in San Antonio, Texas. The experience gained with this business venture provided the foundation and industry understanding that Continue Reading...

  • Nicanor Sangurima – (CPT) Chief Product Technician

    He has decades of experience in botanical studies. Mr. Sangurima was born in Sucua, Ecuador and today holds dual Ecuadorian and US citizenship. Mr. Sangurima worked at Loma Linda University in California where he learned liquid chromatography. At The University of Texas in Austin, he became a Research Botanist. Mr. Sangurima worked for Trinity Chemicals where he performed plant extractions and cancer research. Mr. Continue Reading...

Consultants

  • Raymond Lamy

    Mr. Lamy has over twenty-five years of combined pharmaceutical/biotech industry experience in Regulatory Affairs, Clinical Statistical Programming, and Nonclinical Research, focusing on the development and marketing registration of prescription drug/biotechnology products in several therapeutic areas (i.e., oncology, CNS, pain management, anti-infective). Additional experience with nutritional supplements (“nutriceuticals”), OTC monograph products (antifungals and digestive aids), biologics (blood plasma derivatives, human growth hormone), and medical devices for drug Continue Reading...

  • Grace M. Furman, PhD DABT

    Dr. Furman provides professional toxicology services to the pharmaceutical industry as an independent consultant. Dr. Furman made the decision to become independent in mid-2006, at which time she was Senior Director of Regulatory Safety Assessment in Pfizer’s Drug Safety Research and Development department. Dr. Furman began her professional career in Cincinnati as a divisional toxicologist in Procter & Gamble’s Health Care Sector. In Continue Reading...

  • Al Jecminek, BS, JD

    Mr. Jecminek is a seasoned biotechnology/pharmaceutical executive with over 35 years of experience in the legal, intellectual property and business development aspects of the chemical, pharmaceutical and biotech fields for large and small corporate entities. Early on, Mr. Jecminek worked for over 15 years as a research chemist and patent attorney for Shell Oil Company including 12 years in the patents and licensing Continue Reading...

Advisors

  • Ronald Zane, DDS

    Dr. Zane was born and lived in Hawaii through High School. He graduated from La Sierra University with a BA in Biology. He continued his education at the University of Colorado and Loma Linda School of Dentistry in California. Dr. Zane served in the Unites States Air Force as a Captain performing dentistry. From 1959 – 2003 owned a private dental practice Continue Reading...

  • Thomas E. Williams, MD

    Dr. Williams’ experience in the development of drugs for the treatment of cancer and hematologic malignancies spans more than 40 years. He has 22 years in pharmaceutical research and 20 in academia. He has 22 years in pharmaceutical research and 20 in academia. In 1979, he joined Burroughs Wellcome Company where he served in various positions culminating as the Head of the Section Continue Reading...

  • John K. Whisnant, MD

    Dr. Whisnant began his career in cancer drug development when he joined Burroughs Wellcome in 1978 after certification by the American Board of Allergy and Immunology. At Wellcome, he led the department that developed C. parvum, gamma interferon, and alemtuzumab for treatment of cancers including hematologic malignancies. He rose to senior management positions at DuPont, Fujisawa, Coley Pharmaceuticals and Novo Nordisk. Dr. Whisnant has Continue Reading...